SCHEMBL105937

SCHEMBL105937

CC(C)CCC(=O)Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
TSHR P16473 1/20 0.50
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
AKR1B1 P15121 1/20 0.48
LMNA P02545 1/20 0.47
PKM P14618 1/20 0.47
POLB P06746 1/20 0.47
VNN1 O95497 1/20 0.46
PSMB8 P28062 1/20 0.44
PSMB5 P28074 1/20 0.44
CNR2 P34972 2/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15726475 0.89 L3MBTL1 (0.51) L3MBTL1TDP1TSHRCES2CES1
SCHEMBL15726431 0.87 L3MBTL1 (0.50) L3MBTL1TDP1TSHRCES2CES1
SCHEMBL108334 0.83 CA2 (0.48) L3MBTL1TDP1LMNA
SCHEMBL7450667 0.83 ALDH1A1 (0.55) L3MBTL1TDP1TSHRLMNAPKM
SCHEMBL8619264 0.81 CES1 (0.64) L3MBTL1TDP1TSHRCES2CES1
SCHEMBL6572384 0.80 LMNA (0.63) TDP1LMNAPKMHPGDKMT2A
SCHEMBL106992 0.80 TSHR (0.53) L3MBTL1TDP1TSHRCES2CES1
SCHEMBL6384763 0.80 TDP1 (0.46) L3MBTL1TDP1TSHRCES2CES1
SCHEMBL7517742 0.80 MMP9 (0.49) L3MBTL1TDP1TSHRLMNAPKM
SCHEMBL8966822 0.79 HTT (0.53) L3MBTL1TDP1VNN1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115724729-B 1-Aryl-alpha, beta-unsaturated ketone compound, synthesis method thereof and application thereof in preparation of root-knot nematode killing drugs 陕西省生物农业研究所 2024-05-17 CN claimed
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 EP disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 US disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 US disclosed
CN-115724729-B 1-Aryl-alpha, beta-unsaturated ketone compound, synthesis method thereof and application thereof in preparation of root-knot nematode killing drugs 陕西省生物农业研究所 2024-05-17 CN disclosed
US-11821047-B2 High pressure zone formation for pretreatment Apalta Patent OÜ (EE) 2023-11-21 US disclosed
US-20230295678-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2023-09-21 US disclosed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
EP-1404325-A2 METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY GUILFORD PHARMACEUTICALS INC. (US) 2004-04-07 EP disclosed
WO-2002096420-A2 METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY GUILFORD PHARMACEUTICALS INC. (US) 2002-12-05 WO disclosed
WO-2001079177-A1 CYCLIC DIAZA COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS GPI NIL HOLDINGS, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA L3MBTL1 4522/4885TDP1 2746/4885TSHR 3426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.